GSK (GSK) Expected to Announce Earnings on Wednesday

GSK (NYSE:GSK - Get Free Report) is anticipated to release its Q4 2024 earnings data before the market opens on Wednesday, February 5th. Analysts expect GSK to post earnings of $0.44 per share and revenue of $7.75 billion for the quarter. GSK has set its FY 2025 guidance at 2.090-2.130 EPS.Individual interested in listening to the company's earnings conference call can do so using this link.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a net margin of 7.97% and a return on equity of 50.62%. On average, analysts expect GSK to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

GSK Stock Down 3.5 %

NYSE GSK traded down $1.33 during trading hours on Thursday, hitting $36.38. The company had a trading volume of 7,166,655 shares, compared to its average volume of 4,648,455. The company has a market capitalization of $75.39 billion, a price-to-earnings ratio of 23.62, a P/E/G ratio of 1.38 and a beta of 0.64. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. GSK has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The firm's 50 day moving average is $34.17 and its 200 day moving average is $37.60.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be paid a dividend of $0.3932 per share. The ex-dividend date is Friday, February 21st. This is an increase from GSK's previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a dividend yield of 4.32%. GSK's dividend payout ratio (DPR) is currently 96.10%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on GSK. Guggenheim lowered shares of GSK from a "buy" rating to a "neutral" rating in a research note on Thursday, October 31st. StockNews.com lowered GSK from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, January 21st. Deutsche Bank Aktiengesellschaft cut shares of GSK from a "buy" rating to a "hold" rating in a research note on Friday, November 15th. Finally, Jefferies Financial Group downgraded shares of GSK from a "buy" rating to a "hold" rating and dropped their price target for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Six analysts have rated the stock with a hold rating, one has given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.